GLP-1类制剂还为NASH的治疗带来了希望,一些针对NASH适应症的GLP-1类制剂已进入II/III期临床研究。目前的研究显示,GLP-1RA单药治疗可改善 NASH,但不改善肝纤维化;GLP-1/葡萄糖依赖性促胰岛素肽(GIP)双靶点可显著改善NASH;而 GLP-1/GIP/胰高血糖素受体(GCGR)三靶点治疗可使 90% 以上NASH患者实现肝脏脂肪正常...
GLP-1类制剂还为NASH的治疗带来了希望,一些针对NASH适应症的GLP-1类制剂已进入II/III期临床研究。目前的研究显示,GLP-1RA单药治疗可改善NASH,但不改善肝纤维化;GLP-1/葡萄糖依赖性促胰岛素肽(GIP)双靶点可显著改善NASH;而GLP-1/GIP/胰高血糖素受体(GCGR)三靶点治疗可使90%以上NASH患者实现肝脏脂肪正常化。 G...
对于长期坚持治疗的慢性肝病合并2型糖尿病患者,GLP1激动剂可能会降低MALO 风险。这表明GLP1激动剂是降低合并2型糖尿病患者慢性肝病进展风险的有前景药物,期待未来随机试验进一步证实。 参考文献:(上下滑动查看更多) [1] Wester A, Shan...
There’s also a similar class of medications calleddualGLP-1/GIP receptor agonists. There’s currently one of these medications on the market. It’s calledtirzepatide(Mounjaro®). dual :双重的 How do GLP-1 agonists work? To understand how GLP-1 agonists work, it helps to understand how...
SURE Canada研究是一项多中心前瞻性观察性研究,讨论了真实世界中索马鲁肽治疗2型糖尿病的疗效和安全性。文章共纳入了356例使用索马鲁肽治疗的2型糖尿病患者,基线Hb1Ac为8.1%。 随访30周,索马鲁肽的平均剂量为0.76mg q1w,平均Hb1Ac降低了0.9%,体重平均减少了4.3kg,近一半的患者HbA1c<7.0%,40%的患者减重>5%。
5 Bea S, Son H, Bae JH, Cho SW, Shin JY, Cho YM. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study. Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom...
This cohort study examines the association of periconceptional use of glucagon-like peptide 1 (GLP-1) receptor agonists or other noninsulin second-line
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular event
GLP-1 receptor agonists lower body weight by their influence on the central nervous system. • GLP-1 R reduce cardiovascular events (myocardial infarction, stroke, and associated mortality). Abstract Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat...
Therefore, GLP-1 plays a very active role both in the treatment and pathogenesis of diabetes. Multiple physiological effects of GLP-1[1] Medications for diabetes comprise either GLP-1 receptor agonists, with short (one or two daily injections: Exenatide, Liraglutide, Lixisenatide) or long ...